Optimizing Care for Lower-Risk Myelodysplastic Syndromes: Translating Evidence to Clinical Practice - Episode 7
Panelists discuss how they determine thresholds for changing therapy in patients with MDS, evaluate second-line treatment options including the potential use of ESAs after luspatercept, and offer key takeaways for community colleagues managing similar clinical scenarios.
Video content above is prompted by the following: